Probi AB (PROB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Probi AB (PROB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10145
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Probi AB (Probi) is a biotechnology company develops, produces and markets probiotics. The company offers licenses for its technology and sells finished products in bulk. It focuses on products for the improvement of gastrointestinal health and immune system. It distributes its products to leading food, health-product and pharmaceutical companies in the functional food and consumer healthcare segments. Probi markets its products through four different platforms: Probi Premium, Probi Select, Probi LiveBac and Probi Bio-tract. The company has operational presence in Sweden, Rest of Europe, North America and Rest of world. Probi is headquartered in Lund, Sweden.

Probi AB (PROB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probi AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probi AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Probi AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Probi AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Probi Enters into Research Agreement with Wageningen University 11
Probi Enters into Co-Marketing Agreement with Pharmavite 12
Probi Enters Into Distribution Agreement With Dongkook Pharma 13
Probi Enters Into Agreement With BiO-LiFE Marketing For Probiotic Product 14
Symrise Enters Into R&D Agreement With Probi For Probiotic Products 15
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 16
Probi Enters Into Distribution Agreement With Alvogen 17
USV Enters Into Distribution Agreement With Probi For Vibact IBS 18
Licensing Agreements 19
Ipsen Enters into Licensing Agreement with Probi 19
Acquisition 20
Symrise Completes Acquisition Of Additional 3.53% Stake In Probi 20
Probi AB – Key Competitors 21
Probi AB – Key Employees 22
Probi AB – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 13, 2018: Q2 2018: Regained business momentum and strong margin improvement 24
Oct 25, 2017: Probi: Interim report Q1-Q3 2017 25
May 04, 2017: Probi continues on its successful growth path 29
Jan 10, 2017: Probi – Strong Growth in net Sales and Operating Profit in the Fourth Quarter 32
Corporate Communications 33
Oct 01, 2018: Probi names Tom Ronnlund as new CEO 33
Jul 19, 2018: Probi announces resignation of Jorn Andreas as CFO 34
Mar 14, 2018: Probi Appoints Ole Sogaard Andersen As Interim CEO 35
Feb 14, 2017: Probi appoints Jorn Andreas as new CFO 36
Government and Public Interest 37
Sep 11, 2017: New clinical study shows that Probi’s probiotics support the immune system and may delay the onset of gluten intolerance in children 37
Product News 38
Feb 06, 2018: Probi’s largest clinical trial confirms the immune enhancing impact of Probi Defendum and sheds new light on the mechanism 38
Other Significant Developments 39
Apr 11, 2018: Probi enters the bone health area – a new area for probiotics 39
Jan 25, 2018: Probi: Q4 – 2017 Year-End Report 40
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Probi AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probi AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probi AB, Deals By Therapy Area, 2012 to YTD 2018 9
Probi AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Probi Enters into Research Agreement with Wageningen University 11
Probi Enters into Co-Marketing Agreement with Pharmavite 12
Probi Enters Into Distribution Agreement With Dongkook Pharma 13
Probi Enters Into Agreement With BiO-LiFE Marketing For Probiotic Product 14
Symrise Enters Into R&D Agreement With Probi For Probiotic Products 15
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 16
Probi Enters Into Distribution Agreement With Alvogen 17
USV Enters Into Distribution Agreement With Probi For Vibact IBS 18
Ipsen Enters into Licensing Agreement with Probi 19
Symrise Completes Acquisition Of Additional 3.53% Stake In Probi 20
Probi AB, Key Competitors 21
Probi AB, Key Employees 22
Probi AB, Subsidiaries 23

List of Figures
Probi AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Probi AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probi AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probi AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Probi AB (PROB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dynavax Technologies Corp (DVAX):製薬・医療:M&Aディール及び事業提携情報
    Summary Dynavax Technologies Corp (Dynavax), formerly Double Helix Corp, is a clinical-stage biopharmaceutical company that develops product candidates for the prevention of infectious and inflammatory disease. The company’s only marketed product Heplisav-B is an adult vaccine for hepatitis B. Its p …
  • Nymox Pharmaceutical Corp (NYMX):医療機器:M&Aディール及び事業提携情報
    Summary Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that undertakes the research and development of therapeutics and diagnostics devices to target the unmet needs of the aging population. The company markets diagnostic products for measuring tobacco product exposure and for the …
  • PT Dirgantara Indonesia:企業の戦略・SWOT・財務情報
    PT Dirgantara Indonesia - Strategy, SWOT and Corporate Finance Report Summary PT Dirgantara Indonesia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Yoshinoya Holdings Co Ltd
    Yoshinoya Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Yoshinoya Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • JSHP Transformer Co Ltd:企業の戦略的SWOT分析
    JSHP Transformer Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Mechel:企業の戦略・SWOT・財務情報
    Mechel - Strategy, SWOT and Corporate Finance Report Summary Mechel - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Sujana Universal Industries Ltd. (SUJANAUNI):企業の財務・戦略的SWOT分析
    Sujana Universal Industries Ltd. (SUJANAUNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Monteloeder S.L.:戦略・SWOT・企業財務分析
    Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report Summary Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Asian Citrus Holdings Ltd (73):企業の財務・戦略的SWOT分析
    Asian Citrus Holdings Ltd (73) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ratnamani Metals and Tubes Ltd:企業の戦略・SWOT・財務情報
    Ratnamani Metals and Tubes Ltd - Strategy, SWOT and Corporate Finance Report Summary Ratnamani Metals and Tubes Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Ecsponent Ltd (ECS):企業の財務・戦略的SWOT分析
    Ecsponent Ltd (ECS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Ballast Nedam NV:企業の戦略・SWOT・財務情報
    Ballast Nedam NV - Strategy, SWOT and Corporate Finance Report Summary Ballast Nedam NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Baron Oil Plc (BOIL):石油・ガス:M&Aディール及び事業提携情報
    Summary Baron Oil Plc (Baron Oil), formerly Gold Oil PLC is an oil and gas exploration and production company. The company identifies and develops crude oil and natural gas interests in Latin America including Peru and Colombia. It holds working interests of Nancy Burdine Maxine oil field, oil and g …
  • LifeScan Inc:医療機器:M&Aディール及び事業提携情報
    Summary LifeScan Inc (LifeScan), a subsidiary of the Johnson & Johnson, develops, manufactures and markets blood glucose monitoring solutions for hospital and home use. The company’s product portfolio includes blood glucose meters; test strips and control solutions; lancing devices; diabetes managem …
  • EnWave Corp (ENW):企業の財務・戦略的SWOT分析
    EnWave Corp (ENW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Synopsys, Inc.:企業のM&A・事業提携・投資動向
    Synopsys, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Synopsys, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Enerjisa Enerji Uretim AS:企業の戦略的SWOT分析
    Enerjisa Enerji Uretim AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Sanofi-Aventis Korea Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Sanofi-Aventis Korea Co Ltd (Sanofi-Aventis), a subsidiary of Sanofi is a developer, manufacturer and distributor of generic drugs and medical equipment. The company’s products include note vials lantus, lantus state solo star, she feeds the main vial la, feed her a solo star la shares, elro …
  • OnKure Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OnKure Inc (OnKure) is a drug developer that discovers and develops epigenetic therapies for the treatment of cancer. The company offers production of specific histone deacetylases inhibitors. Its lead product candidate ONK102 significantly reduces the growth rate of tumors in hematological …
  • CSI Compressco LP (CCLP):企業の財務・戦略的SWOT分析
    Summary CSI Compressco LP (CSI), a subsidiary of TETRA Technologies Inc, is an oilfield consulting company that offers compression services and equipment for natural gas and oil production, transportation, and storage. The company's products include real-time compressor monitoring systems, electrica …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆